554 related articles for article (PubMed ID: 31462566)
21. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
22. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
[TBL] [Abstract][Full Text] [Related]
23. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
24. CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections.
Wetzel KS; Yi Y; Elliott STC; Romero D; Jacquelin B; Hahn BH; Muller-Trutwin M; Apetrei C; Pandrea I; Collman RG
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903799
[TBL] [Abstract][Full Text] [Related]
25. Is there a future for antiviral fusion inhibitors?
Berkhout B; Eggink D; Sanders RW
Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
[TBL] [Abstract][Full Text] [Related]
27. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
[TBL] [Abstract][Full Text] [Related]
28. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
29. In vitro inhibitory effect of maraviroc on the association of the simian immunodeficiency virus envelope glycoprotein with CCR5.
Giraudy I; Ovejero CA; Affranchino JL; González SA
Virus Genes; 2021 Feb; 57(1):106-110. PubMed ID: 33400102
[TBL] [Abstract][Full Text] [Related]
30. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
Virol J; 2008 May; 5():56. PubMed ID: 18452606
[TBL] [Abstract][Full Text] [Related]
31. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.
Ji C; Kopetzki E; Jekle A; Stubenrauch KG; Liu X; Zhang J; Rao E; Schlothauer T; Fischer S; Cammack N; Heilek G; Ries S; Sankuratri S
J Biol Chem; 2009 Feb; 284(8):5175-85. PubMed ID: 19097993
[TBL] [Abstract][Full Text] [Related]
32. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
[TBL] [Abstract][Full Text] [Related]
33. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
34. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
[TBL] [Abstract][Full Text] [Related]
35. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
36. Dualtropic CXCR6/CCR5 Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabey Primary Lymphocytes: Distinct Coreceptor Use in Natural versus Pathogenic Hosts of SIV.
Elliott ST; Wetzel KS; Francella N; Bryan S; Romero DC; Riddick NE; Shaheen F; Vanderford T; Derdeyn CA; Silvestri G; Paiardini M; Collman RG
J Virol; 2015 Sep; 89(18):9252-61. PubMed ID: 26109719
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
38. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity.
Joshi A; Nyakeriga AM; Ravi R; Garg H
J Biol Chem; 2011 Oct; 286(42):36404-13. PubMed ID: 21859712
[TBL] [Abstract][Full Text] [Related]
39. Specific reactions between purified HIV-1 particles and CD4+ cell membrane fragments in a cell-free system of virus fusion or entry.
Harada T; Tatsumi M; Takahashi H; Sata T; Kurata T; Kojima A
Microbes Infect; 2004 Apr; 6(5):421-8. PubMed ID: 15109956
[TBL] [Abstract][Full Text] [Related]
40. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
